Physicians Experience with SGLT- 2 Inhibitors In Type 2 Diabetic Patients

Background: Approximately, 104 (55%) physicians reported hypertension (HTN), obesity, chronic kidney disease (CKD) and hyperuricemia as the most prevalent comorbidities in diabetic patients. Objectives: This study investigates the experience of Pakistani physicians regarding the use of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors in the management of Type 2 Diabetes (T2D). This cross-sectional survey study was conducted from 1st October to December 31st, 2023, enrolled 189 physicians. Methods: The data was collected by self-administered structured questionnaire which was distributed among physicians across various specialties involved in diabetes care, assessing their views on the efficacy, safety, and economic considerations of SGLT2 inhibitors. Results: Approximately, 104 (55%) physicians reported hypertension (HTN), obesity, chronic kidney disease (CKD) and hyperuricemia as the most prevalent comorbidities in diabetic patients. Empagliflozin was the most prescribed among SGLT-2 inhibitor in patients with heart failure. Approximately, 50% of the physicians advise SGLT-2 inhibitor frequently to their patients. Approximately, 81% of the physicians considered efficacious medicine with cost- benefits for their patients and also 89% of them agreed that the cost and quantity of daily diabetes medications impact a patient's overall diabetes management. Conclusion: The study emphasizes the importance of addressing these economic challenges to enhance the accessibility and utilization of SGLT2 inhibitors, potentially improving health outcomes for patients with T2D. By highlighting physicians' perspectives, this research contributes to the ongoing conversation on optimizing diabetes treatment in Pakistan.